---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-23-009006"
form_type: "8-K"
ticker: "CNSP"
cik: "0001729427"
company_name: "CNS Pharmaceuticals, Inc."
filed_at: "2023-12-21T23:59:59+00:00"
generated_at: "2026-06-07T09:11:57.484996+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "low"
source: SEC EDGAR
---

# CNS Pharmaceuticals holds virtual investor update; no specific results disclosed

## Summary
- Company held a virtual update meeting on Dec 21, 2023 with CEO John Climcao and CMO Dr. Sandra Silberman.
- Meeting link provided in filing but no financial or clinical data included in the 8-K.
- Filing under Regulation FD; no material new information furnished in the report.

## SEC filing metadata
- accession: 0001683168-23-009006
- form_type: 8-K
- ticker: CNSP
- cik: 0001729427
- company_name: CNS Pharmaceuticals, Inc.
- filed_at: 2023-12-21T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: low
- sec_items: 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1729427/000168316823009006/0001683168-23-009006-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1729427/000168316823009006/cns_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-23-009006
- JSON: https://secwatch.observer/filing/0001683168-23-009006.json
- Plain text: https://secwatch.observer/filing/0001683168-23-009006.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.